Navigation Links
GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer
Date:1/30/2009

Three New Studies Initiated in Other Oncology Settings

LONDON and COPENHAGEN, Denmark, Jan. 30 /PRNewswire-USNewswire/ -- GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Arzerra(TM) (ofatumumab) to treat patients whose chronic lymphocytic leukemia (CLL) is resistant (refractory) to previous therapies. If approved, ofatumumab would be the first anti-CD20 monoclonal antibody available for this patient population.

CLL is the most common form of adult leukemia in the Western world,(1,2) affecting more than 90,000 Americans.(3) Patients with refractory CLL need new therapies since less than 25 percent respond to most current treatments while still having to cope with adverse effects.(4)

"The submission of the BLA for ofatumumab brings us closer to the possibility of providing a new treatment to patients with refractory CLL," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "This is the first BLA ever filed for an antibody produced by Genmab and is a significant achievement in our partnership with GSK."

The submission is based on an analysis that included 138 patients with CLL who showed limited or no response to both fludarabine and alemtuzumab treatment (fludarabine alemtuzumab refractory) and patients who were refractory to fludarabine and considered inappropriate candidates for alemtuzumab due to bulky tumor masses (>5 cm) in their lymph nodes (bulky fludarabine refractory). The primary endpoint of the study was assessment of response. The overall response rate seen in these patient groups treated with single-agent ofatumumab was 58 percent for the fludarabine alemtuzumab refractory group (n=59) and 47 percent for the bulky fludarabine refractory group (n=79).(5,6)

The most common adverse events (AEs) seen with ofatumumab were re
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. GlaxoSmithKlines Drug Will Become New Clinical Gold Standard by 2012 for the Treatment of Relapsed/Refractory CLL
2. GlaxoSmithKline Awards Ten Area Healthcare Nonprofits with $40,000 Each in Funding
3. GlaxoSmithKline and Dynavax Announce Worldwide Strategic Alliance : – Developing First-in-Class Endosomal TLR Inhibitors for Autoimmune and Inflammatory Diseases –
4. GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists
5. GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program
6. GlaxoSmithKline to Acquire the Leading Dry Mouth Brand, Biotene
7. AUDIO from Medialink and GlaxoSmithKline: Give Kids A Boost For Their Health!
8. GlaxoSmithKline Acquires Sirtris Pharmaceuticals, Inc., a World Leader in Sirtuin Research and Development
9. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
10. Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
11. Video: GlaxoSmithKline Consumer Healthcare Offers Free Nicotine Lozenges for All Certified Pilots and Air Traffic Controllers to Help Them Safely Quit Smoking
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... NC (PRWEB) August 29, 2014 Tim ... in the North Carolina General Assembly, spent the morning ... Healthcare and touring our facilities. , Representative Moffitt’s visit ... based durable medical equipment (DME) company and to discuss ... impact DME providers such as Aeroflow. , Josh ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 http://www.fdanews.com/CTMPR ... of Clinical Trials Magnifier Weekly. , Clinical Trial Magnifier ... world every week and reports all the fresh changes. ... is able to extract just the information readers need. ... drill down using links in the newsletter to focus ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 And the results ... the Turks & Caicos Islands, is voted a favorite with ... Best Island in the World in the Travelers' Choice Awards ... year, travelers from all across the globe pick their favorites, ... a winner in multiple categories. , The Venetian ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Recent reports, ... suggested that Americans today are working longer hours and ... and overstressed. APEC Water believes that drinking lots of ... Labor Day Sale on their most popular and effective ... healthy. From now until 9/2/2014, customers can save up ...
(Date:8/29/2014)... August 29, 2014 Until now, databases ... tables) or unstructured data (document stores). SQL products have ... have basically managed the wide assortment of unstructured data. ... work with Big Data is with a NoSQL Database. ... various aspects of all Big Data issues. Scientel ...
Breaking Medicine News(10 mins):Health News:North Carolina Representative Tim Moffitt Visits Aeroflow Healthcare 2Health News:FDAnews Accounces New Newsletter: Clinical Trial Magnifier Weekly Provides the Most Up-to-Date Clinical Trial Data 2Health News:FDAnews Accounces New Newsletter: Clinical Trial Magnifier Weekly Provides the Most Up-to-Date Clinical Trial Data 3Health News:FDAnews Accounces New Newsletter: Clinical Trial Magnifier Weekly Provides the Most Up-to-Date Clinical Trial Data 4Health News:Relax this Labor Day Weekend with Great Savings on Easy-Install, Do-It-Yourself Drinking and Whole House Water Filters 2Health News:Scientel Announces Support for SQL Queries and Relational Tables Within Its Gensonix® NoSQL DB 2Health News:Scientel Announces Support for SQL Queries and Relational Tables Within Its Gensonix® NoSQL DB 3Health News:Scientel Announces Support for SQL Queries and Relational Tables Within Its Gensonix® NoSQL DB 4
... weight loss is an important predictor of poor outcome in ... on // regarding why heart failure patients lose weight or ... focused on elevated levels of angiotensin II, a substance in ... to rise . A study conducted in mice that showed ...
... weight loss may be an early sign of dementia ... the onset of // definite dementia symptoms and accelerates ... the elderly is common and may be associated with ... people who already have dementia. For the study researchers ...
... recent study researchers have linked breathing cancer-causing compounds during ... among offspring. They also believe that nearly all childhood ... inhalation of noxious substances. ,The study compared a ... younger who died from leukemia and other cancers between ...
... brought with it a new lease of life for Organ ... uphill struggle doesn’t stop with finding a matching donor. In ... shown that despite all high tech matching done for liver ... surgeon Ignazio Marino, M.D., of Thomas Jefferson University Hospital in ...
... hormones could be responsible for some of the problems ... measuring levels of five different sex hormones in men ... those found in healthy people. All the MS patients ... brain damage characteristic of the disease. ,Results showed ...
... linked the use of estrogen replacement therapy with a lower ... ) is known as a good indicator of exposure to ... how BMD related to the risk of cognitive problems. All ... beginning of the study. Researchers then measured their BMD at ...
Cached Medicine News:
(Date:8/28/2014)... , Aug. 28, 2014  In recognition of ... health complications from the flu, pneumonia, shingles and ... have declared September to be Senior Vaccination ... age, it is important that adults ages 65 ... their vaccinations. CVS pharmacists and MinuteClinic nurse practitioners ...
(Date:8/28/2014)... , Aug. 28, 2014  Robotic surgery is ... media, both for the promise of improved outcomes ... quick deployment of surgical robots and market pressures ... facilities to evaluate their robotic surgery training programs ... team.    ECRI Institute ( www.ecri.org ...
(Date:8/28/2014)... Ohio , Aug. 28, 2014  A ... competition in generics are adding pressure to pharmaceutical, ... resources. Company resources continue to shrink and approval ... This has led companies to look for additional ... commercialization and for keeping approved products on the ...
Breaking Medicine Technology:September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 2September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 54 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 24 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 34 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 4
... Nov. 3, 2010 Par Pharmaceutical Companies, Inc. (NYSE: ... ended September 30, 2010. For the third quarter ... $234.4 million and income from continuing operations of $30.7 million, ... milestone payment to Tris Pharma, Inc., a $2.3 million payment ...
... OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics ... it has been awarded $1.2 million to support ... Qualifying Therapeutic Discovery Project ("QTDP") program.  All of ... an award.  The funds will be used to ...
Cached Medicine Technology:Par Pharmaceutical Companies Reports Third Quarter 2010 Results 2Par Pharmaceutical Companies Reports Third Quarter 2010 Results 3Par Pharmaceutical Companies Reports Third Quarter 2010 Results 4Par Pharmaceutical Companies Reports Third Quarter 2010 Results 5Par Pharmaceutical Companies Reports Third Quarter 2010 Results 6Par Pharmaceutical Companies Reports Third Quarter 2010 Results 7Par Pharmaceutical Companies Reports Third Quarter 2010 Results 8Par Pharmaceutical Companies Reports Third Quarter 2010 Results 9Par Pharmaceutical Companies Reports Third Quarter 2010 Results 10Par Pharmaceutical Companies Reports Third Quarter 2010 Results 11OncoMed Pharmaceuticals Awarded Five Therapeutic Discovery Project Grants Totaling $1.2 Million 2OncoMed Pharmaceuticals Awarded Five Therapeutic Discovery Project Grants Totaling $1.2 Million 3
Unique criss-cross strapping distributes weight evenly over the torso for ultimate comfort and flexibility. Fully adjustable 2 inch belt and buckle for easy front closure....
Six inch wide elastic belt transfers the apron weight off the shoulders. 0.5mm front and 0.25mm back with a generous overlap for double protection. Shoulder pads included. Also available without wide...
Our 'flex' removes the apron weight from the shoulders while providing back support. Unlike other elastic backs, ours does not wrinkle up, making cleaning easier....
Economically priced - same high quality as our Standard, with 1" ties. Adjustable back ties keep apron snug....
Medicine Products: